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Background
Juvenile idiopathic arthritis (JIA) is the most common
rheumatic disease in children. In the structure of JIA,
systemic arthritis makes 10 – 15 %. Being one of the
variants of JIA it is defined as a heterogeneous disease.
Aim
To analyze the course, treatment and outcome of sys-
temic JIA in children of the Republic of Bashkortostan
(Russia).
Methods
We observed 56 patients, who fell ill in the age of 16, and
were diagnosed systemic JIA. The diagnosis was defined
by the ILAR criteria (Edmonton, 2001) as arthritis and a
documented quotidian fever of at least two week duration,
plus one or more of the following: typical rash, generalized
lymphadenopathy, enlargement of liver or spleen, serositis.
According to the course of disease the patients were
divided into three subgroups:
1. Monocyclic disease course, patients had only one
attack.
2. Polycyclic disease course was characterized by
recurrent episodes of remission without medication.
3. Chronic persistent course, patients had extended
poly-arthritis with or without systemic features.
Results
We observed 33 boys and 23 girls. Mean age of the
patients was 14.5 years (range 2.1-22.3 years). The mean
age at diagnosis was 4.9 years (range 0.9-14.2 years).
Mean disease duration was 9.6 years. 12 (21.4%) patients
had monocyclic disease course, 15 patients (26.8%) had
polycyclic disease course, and 29 patients (51.8%) had
chronic persistent course. All the patients took non-
steroidal anti-inflammatory drugs and oral prednisolone
(0.7 – 1.0 mg/kg/day). 41 patients (73.2%) took intrave-
nous methylprednisolone (20 -30 mg/kg/day) during
three consecutive days. All the patients took disease-
modifying anti-rheumatic drugs, including methotrexate
(100 %) and cyclosporine A (17 patients, 30.3 %). Anti-
TNF agents were used in three patients, but without any
effect. In four patients some positive effect was reached
by taking tocilizumab. Complications: structural injury
(30 cases, 53.6%), growth retardation (22 cases, 39.3%),
osteoporosis (36 cases, 64.3%), amiloidosis (3 cases,
5.3%).
Conclusion
Despite of similarity of clinical manifestations in debut
of systemic arthritis in most patients, disease course
considerably differs on different patients. Prognosis and
outcome of disease may vary from “recovery” to “hard
life-threatening after-effect”.
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